{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-007222","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.712981+00:00","generated_at":"2026-05-16T20:52:53.185609+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cassava Sciences Q3 net loss $10.8M; advances simufilam for TSC epilepsy","bullets":["Net loss of $10.8M ($0.22/share) vs $27.9M loss ($0.58) in Q3 2024; cash $106.1M.","Simufilam proof-of-concept study for TSC-related epilepsy expected to begin H1 2026.","Appointed Joseph Hulihan as CMO (August 2025) and Dawn C. Bir to board (October 2025).","Maintains $31.25M loss contingency for securities litigation settlement; timing unclear.","Cash use guidance for second half 2025 revised downward; year-end cash est. $92-$96M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-007222","json":"https://secwatch.observer/filing/0001171843-25-007222.json","markdown":"https://secwatch.observer/filing/0001171843-25-007222.md","text":"https://secwatch.observer/filing/0001171843-25-007222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/0001171843-25-007222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/f8k_111225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:52:53.185609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}